14 May 2024, No 92

# Latvijas Vēstnesis (Official Gazette)

OFFICIAL GAZETTE OF THE REPUBLIC OF LATVIA OP 2024/92.2

The Saeima has adopted and
the President has proclaimed the
following law:

## Amendments to the Law "On the Procedures for the Coming into Force and Application of the Criminal Law"

To amend Annex 2 of the Law "On the Procedures for the Coming into Force and Application of the Criminal Law" (Reporter on the Saeima of the Republic of Latvia and Cabinet of Ministers, 1998, No. 23; 1999, No. 7, 23; 2000, No. 14.; 2002, No. 12, 23; 2003, No. 2.; 2007, No. 6, 12;
2008, No. 13.; 2009, No. 14.; Latvijas Vēstnesis, 2009, No. 193; 2010, No. 178.; 2011, No. 167, 199; 2012, No. 121.; 2013, No. 38, 92; 2014, No. 123.; 2015, No. 104, 227; 2016, No. 31, 71; 2017, No. 36, 124, 194; 2018, No. 244.; 2019, No. 200A; No. 236A; 2020, 119.C, No. 178, 184; 2021, No. 92A; 2022, No. 76, 110) as follows:

1. Add the following Paragraphs 9 and 10 to the Transitional Provisions of the Law:

"9. The new wording of Section 6(3) of Chapter II, Annex 2 to this Law that lays down exceptions for use during veterinary medicine procedures shall come into force on 1 December 2025.

10. Article 13($59_1$) of Chapter III, Annex 2 to this Law shall come into force on 1 December 2025".

2. Annex 2:

Add the Paragraph $4_1$ to Chapter I as follows:

"$4._1$ "If the chemical composition of any substance in List III corresponds to substances in List II, requirements of List II shall not apply to such substance."

Word Paragraph 5 of Chapter II as follows:

"5. "Synthetic opioid analgesics:

| No. | International Nonproprietary Name (INN)/trivial name of the substance | Chemical Abstracts Service Number *Chemical Abstracts Service* (hereinafter, *CAS* No.) | Chemical name of the substance | Threshold for quantity to be considered low | Threshold for quantity to be considered high |
|---|---|---|---|---|---|
| 1) | alphacetylmethadol (INN) | 1553-31-7 | [(3R*,6R*)-6-dimethylamino-4,4-di(phenyl)heptan-3-yl] | 0.1 g | 1 g |

| | | | | | |
|---|---|---|---|---|---|
| | | | acetate | | |
| 2) | bromadol, BDPC | 77239-98-6 | 4-(4-bromophenyl)-4-(dimethylamino)-1-(2-phenylethyl) cyclohexanol | 0.001 g | 1 g |
| 3) | brorphine | 2244737-98-0 | 1-{1-[1-(4-bromophenyl)ethyl] piperidin-4-yl}-1,3-dihydro-2H-benzymidazol-2-one | 0.01 g | 1 g |
| 4) | faxeladol | 433265-65-7 | 3-[2-[(dimethylamino)methyl]cyclohexyl]phenol | 0.001 g | 1 g |
| 5) | MPPP, desmethylprodine | 13147-09-6 | (4-phenyl-1-methylpiperidin-4-yl)propanoate | 0.1 g | 1 g |
| 6) | PEPAP | 64-52-8 | 4-phenyl-1-(2-phenylethyl)piperidin-4-yl acetate | 0.1 g | 1 g |
| 7) | viminol | 21363-18-8 | α-[[bis(1-methylpropyl)amino]methyl]-1-[(2-chlorophenyl)methyl]-1H-pyrrole-2-methanol | 0.1 g | 1 g |
| 8) | thiobromadol | 616898-54-5 | 4-(4-bromophenyl)-4-(dimethylamino)-1-[1-(2-thienyl)ethyl] cyclohexanol | 0.001 g | 1 g ” |

Amend Paragraph 6(3) of Chapter II as follows:

| | | | | | |
|---|---|---|---|---|---|
| “ 3) | etorphine (excl. for veterinary procedures) | 14521-96-1 | (5alpha,7alpha)-7-(2-hydroxypentan-2-yl)-6-methoxy-17-methyl-4,5-epoxy-6,14-etenomorfinan-3-ol | 0.1 g | 1 g ” |

Amend Paragraph 8(1) of Chapter II as follows:

| | | | |
|---|---|---|---|
| “ 1) | **Derivatives of indole, azaindole and indazole-3-carbonyl**<br>Derivatives of indole-3-carbonyl, azaindole-3-carbonyl and indazole-3-carbonyl that are substituted or unsubstituted at the nitrogen atom of indole or indazole in position 1 with an unsubstituted or substituted alkyl group and in position 3 at the carbonyl group with:<br>a) unsubstituted or substituted alkyl group or cycloalkyl group;<br>b) unsubstituted or substituted aromatic or hetero-aromatic cycle;<br>c) unsubstituted or substituted alkoxy group, an aryloxy group, a heteriloxy group;<br>d) substituted amino group and indole or azaindole cycle in position 2, substituted or unsubstituted with an alkyl group,<br>and any of the above compounds additionally substituted in the indole, azaindole or indazole cycle, including the cycle in which the substitute forms an additional cycle. | 0.003 g | 1 g ” |

Amend Paragraph 8(2)(d) of Chapter II as follows:

“d) by substituting one or more hydrogen atoms in the acetyl group with any substitutent or by including a carbon atom in a cycle that may be substituted, including by forming complementary cycles or by substituting the acetyl group with an ester group that can be substituted”.

Include Paragraphs 8(4), 8(5), 8(6), 8(7) and 8(8) Chapter II as follows:

| | | | |
|---|---|---|---|
| “<br>4) | **4-cinnamylpiperazine-1-carbaldehydes**<br>4-cinnamylpiperazine-1-carbaldehyde and any compound derived from 4-cinnamylpiperazine-1-carbaldehyde:<br>a) by substituting one or several hydrogen atoms in the benzene cycle;<br>b) by substituting one or several hydrogen atoms in the piperazine cycle with a substituted or unsubstituted alkyl group; | 0.001 g | 1 g |
| | c) by substituting the hydrogen atom at the carbonyl group with an unsubstituted or substituted alkyl group. | | |
| 5) | **N-[1-(2-phenylethyl)-2-piperidilidene] benzenesulfonamides**<br>N-[1-(2-phenylethyl)-2-piperidilidene] benzenesulfonamide and any compound derived from N-[1-(2-phenylethyl)-2-piperidilidene] benzenesulfonamide:<br>a) by substituting one or several hydrogen atoms in one or both benzene cycles;<br>b) by substituting one or several hydrogen atoms in the piperidine cycle with substituted or unsubstituted alkyl groups. | 0.001 g | 1 g |
| 6) | **N-(2-aminocyclohexyl) benzamides and N-(2-aminocyclohexyl)-2-phenylacetamides**<br>N-(2-aminocyclohexyl) benzamide and N-(2-aminocyclohexyl)-2-phenylacetamide and any compound derived from N-(2-aminocyclohexyl)benzamide and N-(2-aminocyclohexyl)-2-phenylacetamide:<br>a) by not substituting or substituting one or both hydrogen atoms of the amino group or by including it in a cycle;<br>b) by not substituting or substituting the hydrogen atom in the amide group;<br>c) by not substituting or substituting hydrogen atoms in the benzene or cyclohexane ring with one or several similar or different substituents, including by forming complementary cycles;<br>d) by substituting the benzene ring with another cyclic aromatic structure that differs from that of the benzene ring that can be substituted. | 0.001 g | 1 g |
| 7) | **N-[(1-aminocyclohexyl)methyl] benzamides**<br>N-[(1-aminocyclohexyl)methyl] benzamide and any compound derived from N-[(1-aminocyclohexyl)methyl] benzamide:<br>a) by substituting one or both hydrogen atoms of the amino group or by including it in the cycle;<br>b) by substituting the hydrogen atom in the amide group;<br>c) by not substituting or substituting hydrogen atoms in the benzene or cyclohexane ring with one or several similar or different substituents, including by forming complementary cycles;<br>d) by substituting the benzene ring with another cyclic aromatic structure that differs from that of the benzene ring that can be substituted. | 0.001 g | 1 g |
| 8) | **N-(2-aminocyclohexyl)-N-phenylformamides**<br>N-(2-aminocyclohexyl)-N-phenylformamide and any compound derived from N-(2-aminocyclohexyl)-N-phenylformamide:<br>a) by substituting one or both hydrogen atoms of the amino group or by including it in the cycle;<br>b) by not substituting or substituting hydrogen atoms in the benzene or cyclohexane ring with one or several similar or different substituents, including by forming complementary cycles;<br>c) by substituting the hydrogen atom at the carbonyl group with an unsubstituted or substituted alkyl group or cyclic structure. | 0.001 g | 1 g<br>” |

Amend Paragraph 11(1) of Chapter II as follows:

| | | | |
|---|---|---|---|
| “ 1) | **2,5-dimetoxifenyl ethanamines**<br>2,5-dimetoxifenyl ethanamine and any compound derived from 2-(2,5-dimetoxifenyl) ethanamine:<br>a) by substituting hydrogen atom(s) in the benzene ring with one or several similar or different substituents or substituents that create a cyclic structure supplementing the benzene ring;<br>b) by substituting hydrogen atom(s) in the ethylene group;<br>c) by substituting one or two hydrogen atoms at the nitrogen atom with an unsubstituted or substituted alkyl group or by including a nitrogen atom in the cycle;<br>d) in any of the above compounds, by substituting the hydrogen atom at the nitrogen atom, if it is free, with an unsubstituted or substituted hydroxyl group or acyl group. | 0.02 g | 2 g ” |

Amend Paragraph 11(6)(a) of Chapter II as follows:

| | | | |
|---|---|---|---|
| “ a) | 2-amino-1-phenylpropan-1-one and any compound derived from 2-amino-1-phenylpropan-1-one:<br>a) by not substituting or substituting one or two hydrogen atoms at the nitrogen atom with an unsubstituted or substituted alkyl group or alkoxy group or by including a nitrogen atom in the cycle;<br>b) by not substituting or substituting one or two hydrogen atoms at the propanone position 3 with an unsubstituted or substituted alkyl group or alkoxy group, or amino group;<br>c) by not substituting or substituting hydrogen atoms at the propanone position 2 with an unsubstituted or substituted alkyl group;<br>d) by forming a cyclic structure between the propanone carbon atoms at the position 2 and position 3;<br>e) by replacing the benzene ring in compounds in sub-paragraphs a) and b) with another cyclic non-benzene structure that can be substituted;<br>f) by replacing the hydrogen atoms of the benzene ring in compounds in sub-paragraphs a) and b) with one or several similar or different substituents or substituents that create a cycle supplementing the benzene ring;<br>g) derivatives of any of the above carbonyl groups or amino groups, or both. | 0.02 g | 3 g ” |

Amend the text in brackets in Paragraph 11(7) of Chapter II as follows: “**(except trazodone, vortioxetine and masitinib mesilate)**”;

Delete Paragraph 13(1) of Chapter III.

Include Sub-paragraph 13($59_1$) of Chapter III as follows:

| | | | | |
|---|---|---|---|---|
| “$59_1$) | lisdexamphetamine | 608137-32-2 | 0.6 g | 10 g ” |

Amend Paragraph 13(82) of Chapter III as follows:

| | | | | |
|---|---|---|---|---|
| “ 82) | oxymorphone (excluding naloxone) | 76-41-5 | 0.2 g | 10 g ” |

Include Sub-paragraph 13($101_1$) of Chapter III as follows:

| | | | | |
|---|---|---|---|---|
| “10$1^{1}$) | thiopental | 76-75-5 | 0.2 g | 10 g ” |

Substitute “gammahydroxybutyric acid (GHB)” in Paragraph 14(10) of Chapter III with “hydroxybutyric acid, gamma (GHB)”;

Include Sub-paragraph 16($8_1$) of Chapter IV as follows:

| | | | | |
|---|---|---|---|---|
| “8$_{1}$) | bromazolam | 71368-80-4 | 0.001 g | 1 g ” |

Include Sub-paragraph 16($10_1$) of Chapter IV as follows:

| | | | | |
|---|---|---|---|---|
| “10$_{1}$) | butorphanol | 42408-82-2 | 0.2 g | 10 g ” |

Include Sub-paragraph 16($15_1$) of Chapter IV as follows:

| | | | | |
|---|---|---|---|---|
| “15$_{1}$) | esketamine | 33643-46-8 | 0.6 g | 10 g ” |

Include Sub-paragraph 16($25_2$) of Chapter IV as follows:

| | | | | |
|---|---|---|---|---|
| “25$_{2}$) | flubromazepam | 2647-50-9 | 0.05 g | 10 g ” |

Include Sub-paragraph 16($61_2$) of Chapter IV as follows:

| | | | | |
|---|---|---|---|---|
| “61$_{2}$) | primidone | 125-33-7 | 0.6 g | 10 g ” |

Include Sub-paragraph 16($66_1$) of Chapter IV as follows:

| | | | | |
|---|---|---|---|---|
| “66$_{1}$) | tiletamine | 14176-49-9 | 0.6 g | 10 g ” |

Include Paragraph 16($71_1$) in Chapter IV as follows:

| | | | | |
|---|---|---|---|---|
| “71$_{1}$) | zolazepam | 31352-82-6 | 0.6 g | 10 g ” |

Amend Paragraph 18 of Chapter V as

follows: "18 Category I precursors:

| No. | Substance name | CAS No. | Threshold for quantity to be considered low | Threshold for quantity to be considered high |
|---|---|---|---|---|
| 1) | alpha-phenylacetoacetamide (APAA) | 4433-77-6 | 10 g | 100 g |
| 2) | alpha-phenylacetoacetonitrile (APAAN) | 4468-48-8 | 10 g | 100 g |
| 3) | diethyl(phenylacetyl)propanedioate (DEPAPD) | 20320-59-6 | 10 g | 100 g |
| 4) | ephedrine | 299-42-3 | 0.6 g | 10 g |
| 5) | ergometrine | 60-79-7 | 50 g | 1 kg |
| 6) | ergotamine | 113-15-5 | 50 g | 1 kg |
| 7) | ethyl alpha-phenylacetoacetate (EAPA) | 5413-05-8 | 10 g | 100 g |
| 8) | ethyl 3-(2H-1,3-benzodioxol-5-yl)-2-methyloxyrane-2-carboxylate (PMK ethyl glycidate) | 28578-16-7 | 10 g | 100 g |
| 9) | isosafrole (*cis* + *trans*) | 120-58-1 | 50 g | 1 kg |
| 10) | lisergic acid | 82-58-6 | 10 g | 100 g |
| 11) | methyl 3-oxo-2-(3,4-methylenedioxyphenyl)butanoate (MAMDPA) | 1369021-80-6 | 10 g | 100 g |
| 12) | methyl alpha-phenylacetoacetate (MAPA) | 16648-44-5 | 10 g | 100 g |
| 13) | methyl-2-methyl-3-phenyloxyrane-2-carboxylate (BMK methyl glycidate) | 80532-66-7 | 10 g | 100 g |
| 14) | methyl-3-(1,3-benzodioxol-5-yl)-2-methyloxyrane-2-carboxylate (PMK methyl glycidate) | 13605-48-6 | 10 g | 100 g |
| 15) | N-acetylanthranilic acid | 89-52-1 | 50 g | 1 kg |
| 16) | N-phenyl-1-(2-phenylethyl)piperidine-4-amine (ANPP) | 21409-26-7 | 0.6 g | 10 g |
| 17) | N-phenyl-N-(piperidine-4-yl)propaneamide (norfentanyl) | 1609-66-1 | 10 g | 100 g |
| 18) | N-phenylpiperidine-4-amine (4-AP) | 23056-29-3 | 10 g | 100 g |
| 19) | norephedrine | 14838-15-4 | 0.6 g | 10 g |
| 20) | piperonal | 120-57-0 | 50 g | 1 kg |
| 21) | pseudoephedrine | 90-82-4 | 0.6 g | 10 g |
| 22) | safrole | 94-59-7 | 50 g | 1 kg |
| 23) | terc-butyl 4-anilinepiperidine-1-carboxylate (1-boc-4-AP) | 125541-22-2 | 10 g | 100 g |
| 24) | 1-(2-phenylethyl)piperidine-4-one (NPP) | 39742-60-4 | 0.6 g | 10 g |
| 25) | 1-phenyl-2-propanone (BMK) | 103-79-7 | 10 g | 100 g |
| 26) | 2-methyl-3-phenyloxyrane-2-carboxylic acid (BMK glycidic acid) | 25547-51-7 | 10 g | 100 g |

| | | | | |
|---|---|---|---|---|
| 27) | 3-(1,3-benzodioxol-5-yl)-2-methyloxyrane-2-carboxylic acid (PMK glycidic acid) | 2167189-50-4 | 10 g | 100 g |
| 28) | 3,4-methylenedioxy-phenyl-2-propanone (PMK) | 4676-39-5 | 10 g | 100 g |
| 29) | (1R,2S)-(-)-chloroephedrine | 110925-64-9 | 0.6 g | 10 g |
| 30) | (1S, 2R)-(+)-chloroephedrine | 1384199-95-4 | 0.6 g | 10 g |
| 31) | (1S,2S)-(+)-chloropseudoephedrine | 73393-61-0 | 0.6 g | 10 g |
| 32) | (1R,2R)-(-)-chloropseudoephedrine | 771434-80-1 | 0.6 g | 10 g ” |

3. Delete Paragraph 9 of Annex 3.

The law was adopted by the Saeima on 9 May 2024.

President of Latvia *E. Rinkēvičs*

Riga, 14 May 2024